Literature DB >> 16272888

Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats.

Qing Lu1, Yi-Zhun Zhu, Peter T-H Wong.   

Abstract

The cerebral protective effects of 4-week treatment with candesartan (0.3, 1, 3 mg/kg/day) and ramipril (0.5, 1.5, 5 mg/kg/day) were examined in spontaneous hypertensive rats 24 h after middle cerebral artery occlusion. We found that both candesartan and ramipril could reduce the infarct volume and neurological deficit scores compared with control. Importantly, the neuroprotective effects of candesartan (1 mg/kg/day) were abolished by PD123319 (an AT2 receptor antagonist, 10 mg/kg/day). AT1 receptor gene expression was downregulated while AT2 receptor gene expression was upregulated by candesartan. It is concluded that candesartan appears to provide beneficial effects against stroke in spontaneous hypertensive rats in three ways: AT1 receptor antagonism, downregulation of AT1 receptor expression and upregulation of AT2 receptor expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272888     DOI: 10.1097/01.wnr.0000187636.13147.cd

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  18 in total

1.  The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke.

Authors:  John S Smeda; Noriko Daneshtalab
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-21       Impact factor: 6.200

2.  Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure.

Authors:  Helge Müller-Fielitz; Antonie Markert; Christian Wittmershaus; Friedrich Pahlke; Olaf Jöhren; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-03       Impact factor: 3.000

3.  Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats.

Authors:  Claudia A McCarthy; Antony Vinh; Alyson A Miller; Anders Hallberg; Mathias Alterman; Jennifer K Callaway; Robert E Widdop
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

4.  Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function.

Authors:  Santoshkumar Tota; Kashif Hanif; Pradeep Kumar Kamat; Abul Kalam Najmi; Chandishwar Nath
Journal:  Psychopharmacology (Berl)       Date:  2012-02-24       Impact factor: 4.530

Review 5.  The protective arms of the renin-angiontensin system in stroke.

Authors:  Claudia A McCarthy; Lachlan J Facey; Robert E Widdop
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

6.  AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion.

Authors:  Veysel Haktan Ozacmak; Hale Sayan; Alpay Cetin; Aysenur Akyildiz-Igdem
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

7.  ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity.

Authors:  Michelle J Porritt; Michelle Chen; Sarah S J Rewell; Rachael G Dean; Louise M Burrell; David W Howells
Journal:  J Cereb Blood Flow Metab       Date:  2010-04-21       Impact factor: 6.200

8.  AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.

Authors:  Ahmed Alhusban; Anna Kozak; Adviye Ergul; Susan C Fagan
Journal:  J Pharmacol Exp Ther       Date:  2012-12-04       Impact factor: 4.030

9.  Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.

Authors:  Adam P Mecca; Timothy E O'Connor; Michael J Katovich; Colin Sumners
Journal:  Exp Physiol       Date:  2009-05-08       Impact factor: 2.969

Review 10.  Multifunctional actions of approved and candidate stroke drugs.

Authors:  Jens Minnerup; Wolf-Rüdiger Schäbitz
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.